Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.30 |
| ▸ | FAAH | O00519 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27009146 | 0.83 | CYP2D6 (0.31) | CYP2D6CYP2C19 | |
| SCHEMBL26599 | 0.82 | LMNA (0.39) | ALDH1A1LMNAUSP2MAPTCYP3A4 | |
| SCHEMBL12141363 | 0.80 | TSHR (0.34) | ALDH1A1LMNAUSP2MAPTCYP3A4 | |
| SCHEMBL17173449 | 0.75 | ALDH1A1 (0.31) | ALDH1A1LMNAUSP2MAPTCYP3A4 | |
| SCHEMBL3332532 | 0.75 | — | — | |
| SCHEMBL29268375 | 0.74 | — | — | |
| SCHEMBL13038544 | 0.74 | USP2 (0.37) | ALDH1A1LMNAUSP2MAPTCYP3A4 | |
| SCHEMBL16155371 | 0.74 | CYP2D6 (0.38) | ALDH1A1LMNAUSP2MAPTCYP3A4 | |
| SCHEMBL14066220 | 0.74 | ALDH1A1 (0.35) | ALDH1A1LMNAUSP2MAPTCYP3A4 | |
| SCHEMBL1784171 | 0.73 | CA1 (0.36) | ALDH1A1TSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7557176-B2 | Polyhydroxyalkanoic acid having vinyl, ester, carboxyl or sulfonic acid group and producing method therefor | CANON KABUSHIKI KAISHA (JP) | 2009-07-07 | — | — | US | disclosed |
| US-20080064828-A1 | Polyhydroxyalkanoic Acid Having Vinyl, Ester, Carboxyl or Sulfonic Acid Group and Producing Method Therefor | CANON KABUSHIKI KAISHA (JP) | 2008-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064828-A1 | Polyhydroxyalkanoic Acid Having Vinyl, Ester, Carboxyl or Sulfonic Acid Group and Producing Method Therefor | FAR1, ACSL4, ACAD11 | ALDH1A1 224/4885LMNA 4589/4885USP2 780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.